ストックスクリーナーアプリを入手
91.18
1.97%
1.76
アフターアワーズ：
89.43
-1.75
-1.92%
前日終値:
$89.42
開ける：
$87.67
24時間の取引高:
786.23K
Relative Volume:
0.70
時価総額：
$22.92B
収益：
$3.32B
当期純損益:
$-1.26B
株価収益率:
-17.43
EPS:
-5.2311
ネットキャッシュフロー:
$289.80M
1週間 パフォーマンス:
+4.25%
1か月 パフォーマンス:
-15.17%
6か月 パフォーマンス:
-12.75%
1年 パフォーマンス:
-2.29%
1日の値動き範囲:
$87.45
$91.43
1週間の範囲:
$84.78
$91.43
52週間の値動き範囲:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
91.18 | 22.92B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | アップグレード | Goldman | Neutral → Buy |
| 2025-06-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-05-29 | 開始されました | Goldman | Neutral |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2025-01-10 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2024-11-19 | 開始されました | Berenberg | Buy |
| 2024-11-19 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-11-08 | アップグレード | Goldman | Neutral → Buy |
| 2024-09-24 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-16 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-08-07 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-08-02 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-14 | 開始されました | Evercore ISI | In-line |
| 2024-02-23 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-05 | 開始されました | Oppenheimer | Perform |
| 2023-12-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-10-16 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-17 | アップグレード | Redburn | Neutral → Buy |
| 2022-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-08-17 | 開始されました | Cowen | Market Perform |
| 2022-07-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2021-12-16 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-08-11 | アップグレード | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-16 | ダウングレード | Redburn | Neutral → Sell |
| 2021-05-18 | 開始されました | Goldman | Neutral |
| 2021-05-11 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-08-03 | 再開されました | Berenberg | Buy |
| 2020-07-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 開始されました | H.C. Wainwright | Neutral |
| 2020-01-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-11-05 | 開始されました | Wolfe Research | Outperform |
| 2019-11-04 | 開始されました | Berenberg | Buy |
| 2019-11-04 | 開始されました | BofA/Merrill | Buy |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-11-04 | 開始されました | JP Morgan | Overweight |
| 2019-11-04 | 開始されました | SVB Leerink | Outperform |
| 2019-11-04 | 開始されました | UBS | Buy |
すべてを表示
Biontech Se Adr (BNTX) 最新ニュース
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID - TipRanks
BioNTech Shares Navigate Dual Challenges Amid Strategic Shift () - aktiencheck.de
BioNTech's mRNA Vaccine Platform: Current Developments and Strategic Importance for North American I - AD HOC NEWS
HC Wainwright Issues Negative Estimate for BioNTech Earnings - MarketBeat
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright - Defense World
BioNTech SE (STU:22UA) Stock Price, Trades & News - GuruFocus
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - MSN
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout - Meyka
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Short Interest Down 20.7% in March - marketbeat.com
BioNTech's Oncology Pipeline Shows Promise with Significant Survival Data () - aktiencheck.de
BioNTech SE Sponsored ADR Trade Ideas — BSESOF:22UA - TradingView
Total equity of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
EBITDA per share of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next - TipRanks
BioNTech SE Sponsored ADR $BNTX Shares Bought by SG Americas Securities LLC - MarketBeat
BioNTech (NASDAQ:BNTX) Receives Buy Rating from Jefferies Financial Group - defenseworld.net
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
BioNTech Oncology Pipeline Shows Promising Survival Data in Late-Stage Lung Cancer Trials as of Marc - AD HOC NEWS
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer - GlobeNewswire Inc.
AKT I: „ICI VARSOVIE” [c66293] - Fathom Journal
BioNTech Faces Leadership Transition Amid Pivotal Clinical Milestones () - aktiencheck.de
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors? - news.financial
symbol__ Stock Quote Price and Forecast - CNN
125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox - MarketBeat
BioNTech SE Stock (ISIN: US09075V1026) Faces Pressure After Leadership Exodus and Earnings Miss - AD HOC NEWS
BNP Paribas Financial Markets Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech (NASDAQ:BNTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday - Benzinga
BMO cuts BioNTech stock price target on CEO departure plans - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA - MarketBeat
BioNTech tumbles over 19% on fourth quarter earnings miss - Investing.com
Oppenheimer maintains BioNTech stock rating amid leadership exit - Investing.com
BioNTech stock price target lowered to $167 by Clear Street - Investing.com
BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here? - inkl
Truist reiterates Buy on BioNTech stock after revenue guidance - Investing.com
BofA cuts BioNTech stock price target on leadership transition - Investing.com South Africa
Micron and BioNTech among market cap stock movers on Tuesday By Investing.com - Investing.com India
Micron and BioNTech among market cap stock movers on Tuesday - Investing.com
BioNTech (NASDAQ:BNTX) Hits New 1-Year LowHere's What Happened - MarketBeat
BioNTech Q4 Earnings Call Highlights - Yahoo Finance
BioNTech co-founding couple Sahin and Tuereci leaving to create new company - The Globe and Mail
Biontech Se Adr (BNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
1.47%
大文字化:
|
ボリューム (24 時間):